argenx SE

Healthcare · Biotechnology · Netherlands

Last price 892.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 56.37B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system...